| Related Articles |
Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.
Postepy Dermatol Alergol. 2016 Aug;33(4):247-52
Authors: Wasilewska A, Winiarska M, Olszewska M, Rudnicka L
Abstract
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).
PMID: 27605893 [PubMed]
from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2cKUXDL
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου